Theratechnologies Inc. (NASDAQ:THTX) Sees Large Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 31,900 shares, a growth of 212.7% from the January 31st total of 10,200 shares. Based on an average daily volume of 123,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s shares are short sold.

Theratechnologies Stock Performance

Shares of NASDAQ THTX traded up $0.03 during trading hours on Friday, hitting $1.65. The company’s stock had a trading volume of 71,740 shares, compared to its average volume of 117,445. The stock has a market cap of $75.87 million, a price-to-earnings ratio of -16.50 and a beta of 1.26. Theratechnologies has a 12 month low of $1.08 and a 12 month high of $2.18. The business has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $1.45.

Institutional Trading of Theratechnologies

Large investors have recently bought and sold shares of the company. Wealthspire Advisors LLC boosted its position in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after acquiring an additional 20,000 shares in the last quarter. National Bank of Canada FI boosted its position in Theratechnologies by 29.4% during the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after acquiring an additional 42,435 shares in the last quarter. Bank of America Corp DE boosted its position in Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock valued at $30,000 after acquiring an additional 15,400 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Theratechnologies during the 4th quarter valued at approximately $36,000. Finally, Raymond James Financial Inc. bought a new stake in Theratechnologies during the 4th quarter valued at approximately $27,000.

Analyst Upgrades and Downgrades

Separately, Research Capitl raised Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.